For the malignancy classification, we used the ClinVar database and the list of eligible ERBB2 mutations used by Li and colleagues in the publication, which led to the initial approval for T-Dxd in NSCLC [19,20]. Here, ERBB2 is linked to non-small cell lung carcinoma.